Grainyhead like 2 (GRHL2) is one of three mammalian homologues of the grainyhead (GRH) gene. It suppresses the oncogenic epithelialmesenchymal transition (EMT), acting as a tumor suppressor. On the other hand, GHRL2 promotes cell proliferation by increasing human telomerase reverse transcriptase (hTERT) activity, serving as a tumor promoter. According to gene expression profiling, breast cancer can be divided into basal-like (basal A and basal B), luminal-like, HER2 enriched, claudin-low and normal-like subtypes. To identify common and subtype-specific genomic binding sites of GRHL2 in breast cancer, GRHL2 ChIP-seq was performed in three luminal-like and three basal A human breast cancer cell lines. Most binding sites of GRHL2 were found in intergenic and intron regions. 13,351 common binding sites were identified in basal A cells, which included 551 binding sites in gene promoter regions. For luminal-like cells, 6,527 common binding sites were identified, of which 208 binding sites were found in gene promoter regions. Basal A and luminal-like breast cancer cells shared 4711 GRHL2 binding sites, of which 171 binding sites were found in gene promoter regions. The identified GRHL2-binding motifs are all identical to a motif reported for human ovarian cancer, indicating conserved GRHL2 DNA-binding among human cancer cells. Notably, no binding sites of GRHL2 were detected in the promoter regions of several established EMT-related genes, including CDH1, ZEB1, ZEB2 and CDH2 genes. Collectively, this study provides a comprehensive overview of interactions of GRHL2 with DNA and lays the foundation 3 for further understanding of common and subtype-specific signaling pathways regulated by GRHL2 in breast cancer.
Introduction
Breast cancer is the predominant cause of cancer-related death in women aged 20 to 59 years globally [1] . Based on gene expression profiling, breast cancer can be divided into several subtypes with distinct molecular features, which includes luminal-like (luminal A and luminal B), basal-like (basal A and basal B), human epidermal growth factor receptor 2 (HER2)-enriched, claudin-low and normal-like subtypes [2] . Both luminal-like and basal-like subtypes comprise at least 73% of all breast cancers [2] . Conversions of luminal to basal lineage have been observed in mouse breast cancer models [3, 4] but luminallike and basal-like subtypes differ in prognosis and response to therapy. Therefore, it is important to characterize common features and discordances between them.
The GRH gene was discovered in Drosophila and its mammalian homologs have three members (GRHL1, GRHL2 and GRHL3) [5] .
GRH deficiency leads to failure of complete neural tube closure, epidermal barrier formation, trachea elongation and epidermal wound response [5] [6] [7] . GRHL2 is one of three mammalian homologues of the GRH gene, which has been investigated in cancer development.
GRHL2 is located on chromosome 8q22 that is frequently amplified in many cancers, including breast cancer, colorectal cancer and oral squamous cell carcinoma [8] [9] [10] . GRHL2, as an oncogene, positively regulates cell proliferation by enhancing hTERT activity through inhibition of DNA methylation at 5'-CpG island around gene promoter [9] . GRHL2 inhibits cell apoptosis by suppressing death receptor (FAS and DR5) expression in breast cancer cells [8, 11] .
Knockdown of GRHL2 downregulated ERBB3 expression, resulting in inhibition of cell proliferation [11] . On the other hand, GRHL2 was previously reported as a suppressor of oncogenic EMT by the loop of GRHL2-miR200-ZEB1 and regulation of the TGF-β pathway [12] [13] [14] .
These controversial results suggest that the roles of GRHL2 may be tumor-specific through regulating different target genes in different cancers.
Chromatin immunoprecipitation followed by deep sequencing (ChIPseq) is a widely used method to analyze protein-DNA interactions, histone modifications, and nucleosomes on genome-wide scale in living cells by capturing proteins at sites of their binding to DNA [15, 16] .
Previous findings showed that GRHL2 shares a similar DNA-binding motif with other GRHL family members [13, 17, 18] . To date, no studies have investigated the genomic landscape of GRHL2 binding sites across breast cancer subtypes. In this study, we provide a comprehensive overview of binding sites of GRHL2 in the genome of basal A and luminal-like subtypes of breast cancer. 6 
Methods and materials

Cell lines
Human breast cancer cell lines representing luminal-like (MCF7, T47D, BT474), basal A (HCC1806, BT20 and MDA-MB-468), and basal B subtypes (Hs578T) were obtained from the American Type Culture Collection. Cells were cultured in RPMI1640 medium with 10% fetal bovine serum, 25 U/mL penicillin and 25 µg/mL streptomycin in the incubator (37°C, 5% CO2).
Chromatin immunoprecipitation-sequencing (ChIP-seq)
Cells were grown in RPMI-1640 complete medium. Cross-linking was performed by 1% formaldehyde for 10 minutes at room temperature (RT). Then 1M glycine (141 µl of 1M glycine for 1 ml of medium) was used to quench for 5 minutes at RT. Cells were washed twice with icecold PBS containing 5 µl/ml phenylmethylsulfonyl fluoride (PMSF). Cells were harvested by centrifugation (2095 g for 5 minutes at 4°C) and lysed with NP40 buffer (150 mM NaCl, 50mM Tris-HCl, 5mM EDTA, 0.5% NP40, 1% Triton X-100) containing 0.1% SDS, 0.5% sodium deoxycholate and protease inhibitor cocktail (EDTA-free Protease Inhibitor Cocktail, Sigma). Chromatin was sonicated to an average size of 300 bp (Fig. S1 ). GRHL2-bound chromatin fragments were immunoprecipitated with anti-GRHL2 antibody (Sigma; HPA004820). Precipitates were eluted by NP buffer, low salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.1), 150mM NaCl), high salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM
Tris-HCl (pH 8.1), 500mM NaCl) and LiCl buffer (0.25M LiCl, 1%NP40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl (pH 8.1)).
Chromatin was de-crosslinked by 1% SDS at 65°C. DNA was purified by Phenol:Chloroform:Isoamyl Alcohol (PCI) and then diluted in TE buffer.
In order to examine the quality of our samples before sequencing, ChIP-PCR was performed to validate interaction of GRHL2 with the promoter region of CLDN4, a direct target gene GRHL2 [19] . The results confirmed the GRHL2 binding site around the CLDN4 promoter tgccaaagcctaggggaaga. ChIP-PCR data were collected and analyzed using the 2 −ΔΔCt method [20] .
For ChIP-Seq, library preparation and paired-end sequencing were performed by GenomeScan (Leiden, The Netherlands)
ChIP-seq data analysis
Paired-end reads were mapped to the human reference genome (hg38)
using To examine whether the paired-end reads were appended with unwanted adapter sequences, an adapter content test was performed.
The quality control report ( Fig. S3 ) showed that cumulative presence of adapter sequences was <5% in all cell samples, indicating that all data sets could be further analyzed without adapter-trimming. Per base sequence quality of sequencing was examined, which indicated that all sequencing data were of high quality ( Fig. S4 ) and could be further analyzed.
Reads with low mapping quality (≤ Q30) were filtered out. MACS (Table S1 ).
To further investigate if peaks were enriched in promoter regions, read count frequency and density profiling of GRHL2 binding sites within -6000bp ~ +6000bp of the transcription start site (TSS) were analyzed ( Fig. 3) . Consistent with the annotation of binding sites, which showed most GRHL2 binding sites existed in the intergenic regions, the density of GRHL2 binding sites was not increased in the -1000 to +100 promoter region of basal A and luminal-like breast cancer cells.
To 
Identification of a common GRHL2-interaction motif
The MEME-ChIP program was used to identify motifs, all of which were with statistical significance. In each sample, 3 motifs with high E value were shown ( Fig. 5 ), whose core binding was similar to previously published ones [13, [28] [29] [30] . Thus, our ChIP-seq data indicated that GRHL2 motif was highly conserved in human and mouse cells.
GRHL2-binding at EMT-related genes
GRHL2 and OVOL2 support an epithelial phenotype and counteract EMT transcription factor such as ZEB and SNAIL. Some studies have reported that GRHL2 binding sites are present in the intronic region of CDH1 and in the promoter regions of CLDN4 and OVOL2 for activation of transcription and GRHL2 was found to bind the ZEB1 gene as a negative regulator [12, 28, 31, 32] . In our ChIP-seq data, GRHL2 binding sites were observed at CDH1 introns and at promoter regions of CLDN4 and OVOL2 (Fig. 6) . In our study, CLDN4 showed multiple GRHL2 binding sites across the gene coding/non-coding regions, suggesting the binding of GRHL2 to multiple regions may be involved in long-distance chromatin interactions as suggested previously [13] . Conversely, no GRHL2 binding was observed at the promoter of ZEB1 and ZEB2 (Fig. 6) , arguing against mutual regulation through direct interaction as previously suggested [33] .
These findings suggest that GRHL2 binding sites in EMT-related genes may be cell context-dependent.
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Discussion
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Figure legends
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